Board Change • Jun 21
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Senior Independent Non-Executive Director Willy Simon is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • May 20
OKYO Pharma Limited Expands Scientific Advisory Board with Appointment of Marta Sacchetti OKYO Pharma Limited announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. Marta Sacchetti, MD, PhD is Associate Professor of Ophthalmology at Link University in Rome, Italy and brings extensive clinical, research, and industry experience in cornea and ocular surface diseases. Dr. Sacchetti’s previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici will further strengthen the MAB’s global expertise in targeted nerve regeneration, modulating pain signaling, and advanced diagnostic insight. Her research focuses on degenerative, allergic, and neuroimmune diseases of the cornea and ocular surface. She authored numerous publications in international peer reviewed journals, abstracts for national and international conferences, and ophthalmology book chapters. Announcement • Mar 19
Okyo Pharma Limited Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment of NCP. This new quality-of-life (QoL) data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. The presentation, titled: “First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients” will detail the Phase 2a clinical trial results, including reductions in pain as measured by the VAS, improvements in patient-reported QoL measures, as well as signals suggesting potential restoration of corneal nerve structure in NCP patients. In this Phase 2, randomized, double-masked, placebo-controlled study, patients with NCP received either 0.05% urcosimod (n=6) or placebo (n=6) in the Intent-to-Treat (ITT) population. After 12 weeks of treatment, patients receiving urcosimod demonstrated greater improvements across key aspects of emotional well-being and quality of life compared to placebo. These measures were assessed on a 0–10 scale. Notable improvements included: Enjoying life/relationships with other people: mean change from baseline of -4.5 (IQR -6.00 to -0.75) for urcosimod vs. 0 (IQR -4.75 to 1.25) for placebo. Mood: mean change of -1.5 (IQR -5.25 to 0.25) for urcosimod vs. -0.5 (IQR -4.75 to 2.25) for placebo. Time spent thinking about eye pain: mean change of -3.0 (IQR -5.00 to 0.00) for urcosimod vs. -1.5 (IQR -4.00 to 0.00) for placebo. (IQR = Interquartile Range) These secondary findings build on the primary efficacy signals from the trial, where urcosimod previously demonstrated meaningful reductions in pain as measured by the Visual Analogue Scale (VAS). The exploratory patient-reported outcomes data suggest that urcosimod may provide broader therapeutic benefits, contributing to enhanced emotional well-being and overall day-to-day life satisfaction for patients suffering from this debilitating condition. NCP is a severe, chronic ocular pain disorder with no FDA-approved treatments available, representing a major unmet medical need. These results highlight urcosimod's potential holistic profile beyond pain reduction alone. Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year. 
